Entest Biomedical, Inc. Applying for National Institutes of Health (NIH) Grant for Studying Chemotherapy Resistance in Cancer Stems Cells

SAN DIEGO, CA--(Marketwire - February 11, 2010) - Entest BioMedical Inc. (OTCBB: ENTB) is applying for a grant offered jointly between the National Cancer Institute (NCI) and the National Institute on Aging (NIA). Both NCI and NIA are part of the National Institutes of Health. The grant Entest is applying for will involve studying cancer stem cells, specifically looking for characteristics among cancer stem cells leading to chemotherapy resistance.

If approved, Entest could receive up to $500,000 in funding over a two year period. This research dovetails into Entest’s immunotherapeutic cancer vaccine model, as immunotherapy could prove significant in overcoming chemotherapy resistance in tumor cells.

Entest’s Chairman & CEO David Koos noted, “We are interested in isolating cancer stem cells, which are characteristically resistant to chemotherapeutic agents. By isolating these cancer stem cells, we believe a cancer vaccine can be produced with a high efficacy level.”

Currently, the Company’s researchers are examining animal tumors. This research coupled with the immunotherapeutic research in process should assist the Company in rapidly moving forward with the development of a more efficacious treatment for cancer tumors.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT - 576 is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD.

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is the majority owner of Entest BioMedical Inc. BMSN is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.